CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will present at the following upcoming investor conferences:
- Citi’s 13th Annual Biotech Conference in Boston – Panel discussion at 3:15 p.m. ET on Wednesday, September 5, 2018
- Morgan Stanley’s 16th Annual Global Healthcare Conference in New York City – Fireside chat at 2:50 p.m. ET on Wednesday, September 12, 2018
- Leerink Partners 2018 Rare Disease & Oncology Roundtable in New York City – Fireside chat at 10:00 a.m. ET on Wednesday, October 3, 2018
To access a live webcast of these presentations, please visit the Events & Presentations page within the Investor section of the company’s website at www.epizyme.com. A replay of each webcast will be available on the Epizyme website for 60 days following the event.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage
biopharmaceutical company committed to rewriting treatment for cancer
and other serious diseases through novel epigenetic medicines. Epizyme
is broadly developing its lead product candidate, tazemetostat, a
first-in-class EZH2 inhibitor, with studies underway in both solid
tumors and hematological malignancies, as a monotherapy and combination
therapy in relapsed and front-line disease. The company is also
developing a novel G9a program with its next development candidate,
EZM8266, which is targeting sickle cell disease. By focusing on the
genetic drivers of disease, Epizyme's science seeks to match targeted
medicines with the patients who need them. For more information, visit www.epizyme.com.
